# Stacie Weninger

> Stacie Weninger is a Series A investor at F-Prime (Boston) backing Biotechnology and Medical. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [F-Prime](https://shizune.co/investors/profile/f-prime-capital-partners)
- Location: Boston, United States
- Total investments: 7
- Last investment: Jan 2025
- Lead investor: 43%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/stacie-weninger-3842782/

Stacie Weninger is a Series A investor at F-Prime in Boston focused on Biotechnology and Medical. Stacie Weninger is the Executive Director at F-Prime Capital. Prior to this position, she was the Senior Director of Science Programs for the Fidelity Foundations. In 2005, Dr. Weninger served as the Project Manager and Senior Analyst for the Task Force on Women in Science at Harvard University. From 2001-2005, Dr. Weninger was a Senior Scientistat Cell Press for the journal Neuron. Before joining Cell Press, Dr. Weninger was a postdoctoral research fellow at Children’s Hospital Boston and Harvard Medical School with Dr. Bruce Yankner. She was a Howard Hughes Medical Institute predoctoral fellow in the Program in Neuroscience at Harvard University. While a graduate student and postdoctoral research fellow, Dr. Weninger was actively involved in undergraduate teaching, winning six teaching awards.Dr. Weninger received a Ph.D. in neuroscience from Harvard University, and a B.S. degree in chemistry with highest honors from the University of North Carolina, Chapel Hill. She currently chairs the Collaboration for Alzheimer’s Prevention; is President of Alzforum; serves as Chairman of the Board of Directors for Rugen Therapeutics; serves as a member of the Board of Directors for Enspectra, Aratome, Q-State Biosciences, Digital Cognition Technologies, and Target ALS; and she previously served as a founding member of the Board of Directors for Denali Therapeutics (NASDAQ: DNLI) as well as a member of the Board of Directors for Annexon Biosciences, BRI-Alzan (acquired by MeiraGTx), and Inscopix.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 57% |
| Medical | 3 | 43% |
| Health Care | 2 | 29% |
| Life Science | 2 | 29% |
| Therapeutics | 2 | 29% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 57% |
| Series B | 3 | 43% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Atalanta Therapeutics | Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing its proprietary RNA interference platform. | $97M | Series B | Jan 28, 2025 |  |
| Tenvie Therapeutics | Tenvie Therapeutics is a biotechnology company founded to improve patients' lives with neurological, cardiometabolic, and ophthalmic diseases. The company is focused on developing small molecules targeting brain inflammation, metabolic dysfunction, and lysosomal issues, with a robust pipeline inherited from Denali Therapeutics. Tenvie isprogressing a range of therapeutics aimed at addressing neurological, cardiometabolic, and ophthalmic conditions. Its collection of fully owned, highly brain-penetrant, and precisely designed peripherally restricted small molecules targets three main factors of disease: alleviating inflammation, correcting metabolic dysfunction, and rejuvenating lysosomal function. | $200M | Series A | Jan 08, 2025 |  |
| Engrail Therapeutics | Engrail is forging a new direction to reduce the enormous burden of diseases that impact the nervous system. We unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverageour flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization. | $157M | Series B | Mar 19, 2024 |  |
| Neumora Therapeutics | Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. | $400M | Series A | Oct 07, 2021 |  |
| Atalanta Therapeutics | Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing its proprietary RNA interference platform. | $110M | Series A | Jan 11, 2021 |  |
| Denali Therapeutics | Denali Therapeutics is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights intothe genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. | $130M | Series B | Aug 25, 2016 |  |
| Denali Therapeutics | Denali Therapeutics is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights intothe genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. | $217M | Series A | May 14, 2015 |  |

7 of 7 investments shown.

## Co-investors
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 5 deals together
- [Alaska Permanent Fund](https://shizune.co/investors/profile/alaska-permanent-fund) — VC Fund, 2 deals together
- [Flagship Pioneering](https://shizune.co/investors/profile/flagship-ventures) — VC Fund, 2 deals together
- [RiverVest](https://shizune.co/investors/profile/rivervest) — VC Fund, 2 deals together
- [Aberdeen](https://shizune.co/investors/profile/standard-life) — VC Fund, 2 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 1 deal together

## About F-Prime

VC Fund · Cambridge, United States

F-Prime enables companies to turn their boldest ambitions into world-changing breakthroughs in life sciences, technology, healthtech + services, and crypto. Our legacy spans over 50 years, built on the belief that the best investors share the same entrepreneurial spirit of the founders they back—and that conviction still guides us today.Inhealthcare, we focus on therapeutics, medtech, and healthtech + services in a stage-agnostic fashion. In technology, we focus on enterprise software, fintech and frontier tech, and crypto. While we’re early-stage investors by choice, we’ll back exceptional teams at any stage.Today, our $4.8 billion under management support breakthroughs across healthcare and technology. Our seasoned team of scientists, engineers, physicians, operators, and investors bring real world expertise to help companies accelerate their path to scalable growth, always with an eye towards a shared vision—achieving something incredible.

5 contacts available at F-Prime.

| Name | Title | Profile |
| --- | --- | --- |
| Alexander Pasteur | Partner | https://shizune.co/investors/profile/alex-pasteur |
| Sanjay Aggarwal | Venture Partner | https://shizune.co/investors/profile/sanjay-aggarwal-3 |
| Shervin Ghaemmaghami | Operating Partner | https://shizune.co/investors/profile/shervin-ghaemmaghami |
| Stacie Weninger | Executive Director | https://shizune.co/investors/profile/stacie-weninger |
| Ben Gorman | Principal | https://shizune.co/investors/profile/ben-gorman |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Stacie Weninger invest in?

Stacie Weninger invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Stacie Weninger last invest?

The most recent investment recorded for Stacie Weninger closed in Jan 2025. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co